Asthma Spacers Market - By Product Type (AeroChamber, OptiChamber, Volumatic, Inspirease), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies) – Global Forecast 2024 – 2032

Asthma Spacers Market Size

Asthma Spacers Market size was valued at around USD 1.66 billion in 2023 and is anticipated to register a CAGR of 5.5% between 2024 and 2032. Asthma spacers, also known as inhaler spacers or aerosol-holding chambers, are medical devices used in conjunction with metered-dose inhalers (MDIs) to improve the delivery of inhaled medications to the lungs for individuals with asthma or other respiratory conditions.
 

The rising incidence and prevalence of chronic respiratory conditions have become a significant public health concern globally. For instance, according to the World Health Organization (WHO) in 2019, asthma affected about 262 million people, resulting in 455,000 deaths. Thus, as the prevalence of chronic respiratory conditions, including asthma, continues to rise globally, there is a growing need for effective management and treatment options such as asthma spacers.
 

Furthermore, public, and private organizations are investing significantly in research and development activities aimed at innovating and improving various therapeutic respiratory devices. These investments stimulate the development of new and improved spacer devices with enhanced features, such as smart inhalers which is estimated to reach USD 3.3 billion by 2032, dose counters, anti-static chambers, and compact designs, which cater to the evolving needs of patients and healthcare providers.
 

Asthma Spacers Market Trends

There is increasing awareness among healthcare providers and patients about the benefits of using asthma spacers in conjunction with metered-dose inhalers (MDIs). Spacers help optimize the delivery of medication to the lungs by reducing the need for precise coordination between inhaler activation and inhalation.
 

• This awareness has led to greater adoption of asthma spacers among healthcare professionals and patients alike.
   
• Furthermore, ongoing advancements in technology have led to the development of more sophisticated and user-friendly asthma spacer devices. These technological improvements enhance the efficiency of medication delivery, improve patient adherence to treatment regimens, and reduce the risk of side effects associated with asthma medication.
   

Asthma Spacers Market Analysis

Based on product type, the market is segmented into AeroChamber, OptiChamber, Volumatic, Inspirease, and other product types. The AeroChamber segment is estimated to account for USD 641.5 million in 2023.
 

• AeroChamber plays a pivotal role in reducing the amount of medication deposited in the mouth and throat, minimizing the risk of side effects such as oral thrush and hoarseness.
   
• AeroChamber helps individuals coordinate inhalation with medication actuation, making it easier for them to use their inhalers correctly. This promotes proper inhaler technique, ensuring that patients receive the full dose of medication with each use.
   
• AeroChamber provides significant advantages for individuals with asthma, including enhanced medication delivery, reduced side effects, improved inhaler technique, versatility, ease of use, portability, and options suitable for children.
   

The asthma spacers market by distribution channel is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment accounted for around USD 642 million revenue size in 2023.
 

• Hospital pharmacies have experienced healthcare professionals, including pharmacists and pharmacy technicians, providing specialized pharmaceutical care for patients requiring asthma management, including dispensing, and advising on the use of asthma spacer devices within the healthcare setting.
   
• Furthermore, the requirement for precise asthma spacer devices is heightened in hospital pharmacies, facilitating the delivery of advanced, regulated, and comprehensive respiratory care services to patients with asthma and other respiratory conditions within the healthcare setting.
   

North America asthma spacers market accounted for USD 672.2 million revenue in 2023 and is predicted to witness substantial market growth.
 

• The large market share in the asthma spacers sector is correlated with a sophisticated healthcare infrastructure, an increasing prevalence of respiratory conditions such as asthma, rapid technological advancements, significant healthcare expenditure, and the expanding elderly population.
   
• For instance, according to the Asthma and Allergy Foundation of America in 2021, 39.6% of adults aged 18 and older with asthma reported experiencing one or more asthma attacks.
   
• Furthermore, favorable reimbursement policies and government initiatives aimed at respiratory disease management and prevention further propel the market growth for asthma spacer devices in North America.
   

Asthma Spacers Market Share

The asthma spacers industry is competitive in nature, with several large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced products based on different technologies is among a key market strategy. Some of the leading industry players including Cipla, GlaxoSmithKline plc, Koninklijke Philips N.V., Lupin Limited, among others have a notable presence in the market.
 

Asthma Spacers Market Companies

Some of the eminent market participants operating in the asthma spacers industry include:

• Cipla Inc.      
• GlaxoSmithKline plc
• Koninklijke Philips N.V.       
• Koo Medical Equipment      
• Laboratoire ProtecSom
• Lupin Limited
• Mediacare Equipments (India) Pvt. Ltd.
• Monaghan Medical Corporation                           
• PARI GmbH                                            
• Rossmax International Ltd.                                
• Teleflex Incorporated
   

Asthma Spacers Industry News:

• In February 2024, GlaxoSmithKline plc announced the completion of its acquisition of Aiolos Bio (Aiolos), a clinical-stage biopharmaceutical company dedicated to addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. This acquisition provided GSK with access to Aiolos' innovative pipeline and expertise, strengthening its portfolio in respiratory and inflammatory diseases.
   
• In July 2023, Hormosan Pharma GmbH (Hormosan), a subsidiary wholly owned by Lupin in Germany, introduced Luforbec 100/6 (beclometasone 100µg / for moterol 6µg), a fixed combination available in a pressurized metered dose inhaler (pMDI) for managing adult asthma and chronic obstructive pulmonary disease (COPD) in Germany. This unveiling is intended to enhance the company's product range and solidify its competitive edge within the market.
   

The asthma spacers market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• AeroChamber
• OptiChamber
• Volumatic      
• Inspirease
• Other product types

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa